ANALYSIS OF THE RELEVANCE OF MEASURES TO IMPROVE PHARMACOTHERAPY FOR KIDNEY DISEASES

One of the main objectives of treating chronic kidney disease (CKD) is to slow the illness's progression and lower the chance of death. Until recently, new medication classes to supplement renin-angiotensin-aldosterone system (RAAS) inhibitors as the standard of care hardly achieved their main goals. In order to determine what new information adds to the therapy landscape, this systematic literature analysis examined therapies assessed in CKD patients since 1990. The coexistence of type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) significantly increases cardiovascular morbidity and mortality by two to three times compared to patients without CKD. CKD is a major public health concern that is sweeping the country. The care of chronic kidney disease (CKD) includes both pharmaceutical and non-pharmacological strategies, such as dietary salt reduction and lifestyle changes to lower blood pressure. Renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and mineralocorticoid receptor antagonists (MRAs) are the four main pillars of current pharmacological management, all of which have demonstrated cardiovascular and renoprotective benefits. One of the things causing kidney damage to worsen is an incomplete block of aldosterone activity, which is still a problem. Vicadrostat and other aldosterone synthase inhibitors (ASIs) may open up new possibilities for selectively blocking aldosterone synthesis while maintaining cortisol production. Reductions in albuminuria and the possibility of renal protection have been demonstrated in early-phase trials. Is it possible for ASIs to become a fifth pillar in the management of CKD and slow its progression?